Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 6/20 | 0.38 |
| ▸ | MARK4 | Q96L34 | 4/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035280 | 0.82 | TNK2 (0.52) | JAK2BRD4TNK2 | |
| SCHEMBL15041345 | 0.80 | CDK4 (0.48) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035588 | 0.77 | PTK2 (0.38) | MARK3MARK4PTK2WEE1TNK2 | |
| SCHEMBL15035263 | 0.68 | TNK2 (0.48) | TNK2 | |
| SCHEMBL15041578 | 0.67 | CDK4 (0.51) | PTK2JAK2BRD4 | |
| SCHEMBL15035288 | 0.67 | NUAK1 (0.37) | MARK3MARK4PTK2JAK2JAK3 | |
| SCHEMBL15035382 | 0.66 | CDK4 (0.50) | PTK2JAK2BRD4 | |
| SCHEMBL15035451 | 0.65 | CACNA2D1 (0.34) | PTK2 | |
| SCHEMBL15035550 | 0.64 | CACNA2D1 (0.36) | PTK2TNK2NUAK1 | |
| SCHEMBL15035333 | 0.64 | CDK4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | MARK3 822/4885MARK4 675/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.